Medgend Icon


Dexamethasone

Cushing's syndrome is a hormonal disorder. The cause is long-term exposure to too much cortisol, a hormone that your adrenal gland makes. Sometimes, taking synthetic hormone medicine to treat an inflammatory disease leads to Cushing's. Some kinds of tumors produce a hormone that can cause your body to make too much cortisol.

Cushing's syndrome is rare. Some symptoms are:

  • Upper body obesity
  • Thin arms and legs
  • Severe fatigue and muscle weakness
  • High blood pressure
  • High blood sugar
  • Easy bruising

Lab tests can show if you have it and find the cause. Your treatment will depend on why you have too much cortisol. If it is because you have been taking synthetic hormones, a lower dose may control your symptoms. If the cause is a tumor, surgery and other therapies may be needed.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Dexamethasone FDA Approved Drugs

CIPRODEX [CiprofloxacinC17H18FN3O3 : DexamethasoneC22H29FO5]
RX
-
0.3% : 0.1% (otic suspension/drops)
Novartis Pharms CorpJul 18, 2003
  • Treatment of acute otitis externa.
  • Treatment of acute otitis media.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

DEXAMETHASONE [DexamethasoneC22H29FO5]
RX
-
0.5mg (oral tablet)
0.5mg/5ml (oral elixir)
0.75mg (oral tablet)
1.5mg (oral tablet)
1mg (oral tablet)
2mg (oral tablet)
4mg (oral tablet)
6mg (oral tablet)
Par PharmApr 28, 1983
West-ward Pharms IntApproved Prior To Jan 1, 1982
LyneJul 12, 2011
Sti Pharma LlcApproved Prior To Jan 1, 1982
Vintage PharmsMay 11, 2011
Wockhardt Eu OperatnJul 27, 1983
EcrAug 15, 2008
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

DEXAMETHASONE INTENSOL [DexamethasoneC22H29FO5]
RX
-
1mg/ml (oral concentrate)
West-ward Pharms IntSep 1, 1983
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

DEXAMETHASONE SODIUM PHOSPHATE [Dexamethasone Sodium PhosphateC22H28FO8P2Na]
RX
-
eq 0.1% phosphate (ophthalmic, otic solution/drops)
eq 10mg phosphate/ml (injection injectable)
eq 4mg phosphate/ml (injection injectable)
Bausch And LombJul 26, 1996
Sandoz IncJan 16, 1985
Fresenius Kabi UsaApr 22, 2005
Mylan Labs LtdAug 29, 2008
West-ward Pharms IntSep 7, 1982
Aurobindo Pharma LtdDec 1, 2015
LuitpoldJul 21, 1982
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE [Dexamethasone Sodium PhosphateC22H28FO8P2Na]
RX
-
eq 10mg phosphate/ml (injection injectable)
Fresenius Kabi UsaApr 11, 2003
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

DEXASPORIN [DexamethasoneC22H29FO5 : Neomycin Sulfate : Polymyxin B Sulfate]
RX
-
0.1% : eq 3.5mg base/ml : 10,000 units/ml (ophthalmic suspension/drops)
Bausch And LombSep 13, 1995
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

FARYDAK [Panobinostat LactateC21H23N3O2C3H6O3]
RX
-
eq 10mg base (oral capsule)
eq 15mg base (oral capsule)
eq 20mg base (oral capsule)
Novartis Pharms CorpFeb 23, 2015
  • Treatment of multiple myeloma, in combination with bortezomib and dexamethasone.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

KYPROLIS [CarfilzomibC40H57N5O7]
RX
-
30mg/vial (intravenous powder)
60mg/vial (intravenous powder)
Onyx TherapJun 3, 2016
  • Kyprolis is indicated in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
  • Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

MAXIDEX [DexamethasoneC22H29FO5]
RX
-
0.1% (ophthalmic suspension/drops)
Novartis Pharms CorpApproved Prior To Jan 1, 1982
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

MAXITROL [DexamethasoneC22H29FO5 : Neomycin Sulfate : Polymyxin B Sulfate]
RX
-
0.1% : eq 3.5mg base/gm : 10,000 units/gm (ophthalmic ointment)
0.1% : eq 3.5mg base/ml : 10,000 units/ml (ophthalmic suspension/drops)
Novartis Pharms CorpApproved Prior To Jan 1, 1982
Sandoz IncMay 22, 1984
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE [DexamethasoneC22H29FO5 : Neomycin Sulfate : Polymyxin B Sulfate]
RX
-
0.1% : eq 3.5mg base/gm : 10,000 units/gm (ophthalmic ointment)
Bausch And LombJul 25, 1994
Perrigo Co TennesseeJul 31, 1989
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

OZURDEX [DexamethasoneC22H29FO5]
RX
-
0.7mg (intravitreal implant)
AllerganJun 17, 2009
  • Delivering an ocular implant as described in the dosage and administration section of the approved labeling of ozurdex.
  • Intravitreal treatment of diabetic macular edema.
  • Intravitreal treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo).
  • Treatment of macular edema.
  • Treatment of uveitis.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

THALOMID [ThalidomideC13H10N2O4]
RX
-
100mg (oral capsule)
150mg (oral capsule)
200mg (oral capsule)
CelgeneJan 17, 2003
  • Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl).
  • Approval for marketing only under a special restriction program approved by fda called 'system for thalidomide education and prescribing safety' (s.t.e.p.s.).
  • Maintenance therapy for prevention and supression of the cutaneous manifestations of enl recurrence.
  • Method for delivering a drug to a patient in need of the drug, while avoiding the occurence of an adverse side effect known or suspected of being caused by said drug.
  • Treatment of cutaneous manifestations of erythema nodosum leprosum (enl) in connection with a special program approved by fda called 'system for thalidomide education and prescribing safety' (s.t.e.p.s.).
  • Treatment of male patient having a disease or condition responsive to a teratogenic drug.
  • Use in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma.
  • Use of thalidomide in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma.
  • Use of thalidomide in treatment of cutaneous manifestations of erythema nodosum leprosum (enl).
  • Use of thalidomide while preventing the exposure of a fetus or other contraindicated individual to thalidomide.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TOBRADEX [DexamethasoneC22H29FO5 : TobramycinC18H37N5O9]
RX
-
0.1% : 0.3% (ophthalmic suspension/drops)
Novartis Pharms CorpAug 18, 1988
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TOBRADEX ST [DexamethasoneC22H29FO5 : TobramycinC18H37N5O9]
RX
-
0.05% : 0.3% (ophthalmic suspension/drops)
Novartis Pharms CorpFeb 13, 2009
  • Use of a combination of tobramycin and dexamethasone to treat ocular inflammation where an infection or risk of infection exists.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TOBRAMYCIN AND DEXAMETHASONE [DexamethasoneC22H29FO5 : TobramycinC18H37N5O9]
RX
-
0.1% : 0.3% (ophthalmic suspension/drops)
Bausch And LombOct 27, 1999
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.